Our team is on a mission to improve outcomes in cancer treatment

Evolving the approach to drug delivery in solid tumors

TriSalus™ Life Sciences is committed to becoming a premier oncology drug delivery company.

For more than seven years, we've focused on delivering traditional cancer treatments and immuno-oncology (IO) therapeutics into high-pressure solid tumors to address significant unmet needs and poor outcomes. Our novel technology platform, Pressure-Enabled Drug Delivery™ (PEDD), is designed to improve the distribution & penetration of therapy in solid tumors.

The technology has been used in more than 8,000 procedures worldwide for liver cancer and can be applied to a variety of other high-pressure solid tumors including administration of immuno-oncology (IO) drugs.

Our team has a mission to create new technologies with one goal in mind: to make a meaningful difference in the outcomes and lives of cancer patients.

With a dedicated innovation team, we're rapidly advancing to help a broader set of cancer patients.

Meet the Team

Board of Directors

  • Mats L. Wahlström

    Chairman
  • Simone Song

    Director
  • Gene McGrevin

    Director
  • John L. Tullis

    Director
  • Karen Cassidy

    Director
  • Anil Singhal

    Director
  • Mark Lupa

    Director
  • Mary T. Szela

    Director
  • Mary T. Szela

    Director
  • Mats L. Wahlström

    Chairman

    Mr. Wahlström has more than 30 years of experience in the healthcare industry, having served as CEO and CFO of large international companies in the renal field. Mats currently serves as Executive Chairman of KMG Capital Partners, LLC, Chairman of PCI | HealthDev, and Chairman of Caduceus Medical Holdings, Inc. He also serves as the Lead Director and Chairman of the Audit/Finance Committee of Coherus Biosciences, a public biotech company. In addition, he currently serves on the boards of Getinge AB and Alteco Medical AB, both public companies, as well as Triomed AB and Circuit Clinical, Inc.

    Mats served as a director of Health Grades, Inc., a NASDAQ-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010. From January 2004 through December 2009, Mats served as Co-CEO of Fresenius Medical Care North America and from November 2002 through December 2009 as President and CEO of Fresenius Medical Services, which operates more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including President and CEO of Gambro North America as well as CFO of the Gambro Group.

  • Simone Song

    Director

    Mrs. Song has more than 25 years of experience in the healthcare sector. Simone is the Founder and Senior Partner of ORI Capital and the former Head of Goldman Sachs Healthcare Investment Banking for Greater China.

    Prior to joining Goldman Sachs, Simone was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings.

    Simone holds a B.A. in Economics from Fudan University in China and an M.A. in Economics from Claremont Graduate School in the United States.

  • Gene McGrevin

    Director

    With more than 25 years of experience in the medical industry, Gene McGrevin has held senior management positions in global companies including Johnson & Johnson and Kimberly-Clark Corporation. Mr. McGrevin also was instrumental in the expansion and sale of several medical startups.  They include PetNet Pharmaceuticals (sold to Siemens), Microtek Medical Holdings (sold to EcoLabs), and Medivance (sold to C.R. Bard).  In addition, Mr. McGrevin serves on the Boards of the Yerkes Primate Center, Real Time Medical Data and HydroDynamics. Mr. McGrevin holds an MBA from the University of Pennsylvania's Wharton School.  He earned a BA in economics at the University of Pittsburgh.

  • John L. Tullis

    Director

    Mr. Tullis is President and a Partner at Tullis Health Investors, where he is focused especially on healthcare technology and services, medical devices, and international markets. He has more than 19 years of investing and international business experience. Mr. Tullis currently serves as Chairman of CareSync, Inc. and was also an Executive Committee Member of the Board of Directors of the Beacon Council, Miami-Dade's Economic Development Organization, for three years.

    Mr. Tullis hold a Bachelor's degree in Liberal Arts from DePauw University. He received a Graduate Certificate from the University of Virginia's McIntire Business Institute, and a Master's degree in Business Administration from the University of Miami. At ages 14-15, he studied at a Taiwanese boarding school, where he was the school's only non-Chinese student.

  • Karen Cassidy

    Director

    Ms. Cassidy began her career in a start-up at Johnson & Johnson, the Dermatological Division. She spent six years at Xerox, initially as Sales Operation Planning Manager for the U.S., then running worldwide operations for this function, followed by a two-year stint in the field as a Sales Manager. After this operating background, Ms. Cassidy joined Oak Investment Partners for seven years and subsequently co-managed Aetna's Venture Capital Fund. Ms. Cassidy then returned to the operating side in 1991, assuming the CEO role at ImplaMed and VP Business Development roles at Symbiosis and Corvita, which were sold within a seven-year period. As Managing Director at Partisan Management, Ms. Cassidy has recruited and mentored the management team for each company and applied her sales, marketing, and business development expertise to the building of the company. Ms. Cassidy also manages the liquidity events for the Partisan Management companies.

  • Anil Singhal

    Director

    Dr. Singhal is the former Vice President of Early Oncology Development at AbbVie and Head of AbbVie-Redwood City site. During his tenure at AbbVie, he oversaw the global regulatory approvals of Empliciti in multiple myeloma and Zinbryta in multiple sclerosis. As a member of the R&D leadership team, he helped to build an impressive portfolio and key translational science capabilities in oncology, immunology and other diseases. Anil has held senior roles in the US, Japanese and German biopharma / biotechnology industry for over 30 years leading to the approval of Prosorba in rheumatoid arthritis and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington.

    Anil is passionate about the translation of novel science into transforming medicines for cancer patients. Anil holds a Ph.D. from Wakesman Institute of Rutgers University and an Executive MBA from University of Washington.

  • Mark Lupa

    Director

    Dr. Lupa holds a Bachelor's of Science degree from Northwestern University, a Master's degree from the University of Sussex (England) in Biomedical Engineering and completed his doctoral program in Pharmacology from the University of Lund, Sweden. He conducted neuroscience research for 15 years at institutions worldwide, including the University of Colorado and the University of California San Francisco. Dr. Lupa's business experience came first in the brewing industry as founder, CEO and CFO of Tabernash Brewing Company, which was formed in 1993 and merged with Left Hand Brewing in 1998. Dr. Lupa then moved to the private investment company Tango to focus on technology and Life Science investments. He is currently Managing Director of High Country Venture, a venture capital fund in Boulder, Colorado, and has served as founding member of the Board of Directors of Taligen Therapeutics, Sierra Neuropharma, Oberon, DCS Surgical, and Theratogs. Dr. Lupa also served as CFO of Taligen from inception of the company in 2004 until early 2008.

  • Mary T. Szela

    Director

    Ms. Szela has nearly 30 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses, and devising innovative, differentiated strategies for undistinguished products make for a remarkable record. Previously, Ms. Szela served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company's revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus). Ms. Szela held ascending management positions at Abbott Laboratories including President of the company's $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Vice President for global strategic marketing and services. Ms. Szela currently serves as a member of the Board of Directors for Coherus Biosciences. She earned an M.B.A. and a B.S. in nursing, both from the University of Illinois.

Management Team

  • Mary T. Szela

    CEO and President
  • Dan Estay

    Chief Business Officer
  • Anthony Scalese

    Chief Financial Officer
  • James E. Chomas, PhD

    Chief Technology and Oncology Strategy Officer
  • Anni Goldberg

    General Counsel/HR
  • Lynne Aronson

    VP of Regulatory and Quality
  • Mary T. Szela

    Director

    Ms. Szela has nearly 30 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses, and devising innovative, differentiated strategies for undistinguished products make for a remarkable record. Previously, Ms. Szela served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company's revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus). Ms. Szela held ascending management positions at Abbott Laboratories including President of the company's $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Vice President for global strategic marketing and services. Ms. Szela currently serves as a member of the Board of Directors for Coherus Biosciences. She earned an M.B.A. and a B.S. in nursing, both from the University of Illinois.

  • Dan Estay

    Chief Business Officer

    Dan is Chief Business Officer of TriSalus Life Sciences. He has held a variety of executive operational, commercial and business development roles in healthcare businesses, with extensive experience in medical devices. Prior to joining TriSalus, Dan was consulting for early stage medical technology companies and served as co-founder and CEO of SonoVascular, a pre-clinical stage company focused on advancing the treatment of blood clots using intrasvascular ultrasound energy.

    Prior to consulting, Dan was President of Verathon, a stand-alone subsidiary of Roper Technologies focused on medical devices for airway management and bladder volume measurement. Dan was also with Abbott for 11 years and held leadership positions in the areas of general management and business development, including 6 years based in Tokyo, Japan leading the company's vascular device business in Asia Pacific & Japan. Earlier in his career, he worked for Getz Brothers & Co., Johnson & Johnson and LeMare International.

    Dan received his BS degree in Business Administration from Syracuse University and an MBA from the University of Miami.

  • Anthony Scalese

    Chief Financial Officer

    With more than 16 years of experience in accounting, finance, operations and mergers and acquisitions, Mr. Scalese has spent the past 15 years of his career in the high-tech and healthcare industries. He recently served as CFO for Novinda Corp., a clean tech, startup company specializing in air quality control. In addition, Mr. Scalese served as CFO of Zynex Medical, a global medical device manufacturer and CFO of Qualmark Corporation, a publicly held global manufacturer of durability testing equipment. While at Qualmark, he served as President for various subsidiaries as well. He also held positions at Coram Healthcare (now Apria Healthcare), Foundation Health Systems (now Healthnet) and Coca-Cola Enterprises. Mr. Scalese is a Certified Public Accountant licensed in Colorado, received a Master of Business Administration degree from the University of Colorado and a Bachelor of Science degree in Business Administration (Accounting) from Colorado State University.

  • James E. Chomas, PhD

    Chief Technology and Oncology Strategy Officer

    Dr. Chomas has more than 15 years of experience in developing devices from initial concept through clinical trials and has served in leadership positions in both public and venture-backed companies. He co-founded Surefire Medical in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Dr. Chomas is an active member of the growing biosciences community in Colorado, serving on the board of Colorado Biosciences Association (CBSA) as well as working with the Colorado Office of Economic Development and International Trade (OEDIT) to review early stage funding opportunities. He received his Bachelor of Science degree in Engineering from Duke University and completed his doctoral training at the University of Virginia, investigating the use of ultrasound in breast cancer characterization. Since moving from academics to industry, Dr. Chomas has focused his career on finding better ways to detect and treat cancer. In addition, he has authored more than 25 medical device patents.

  • Anni Goldberg

    General Counsel/HR

    With experience in private practice, in house counsel and non-profit senior leadership roles, Anni has broad litigation experience in both state and federal jurisdictions in a wide breadth of litigation matters. Prior to her work with TriSalus Life Sciences, Anni was most recently of counsel at Katten & Temple, a boutique litigation law firm. Anni provided legal counsel on a variety of federal civil litigation matters to senior executives as well as conducting internal employment investigations. A majority of Anni's clients have been in the pharmaceutical and medical device industry.

    Prior to joining Katten & Temple, Anni was President of a not-for-profit company, Counsel for Abbott Laboratories, an associate for Kelley, Drye & Warren and Kirkland & Ellis. She has also served on a variety of not-for-profit boards.

    Anni received her JD from the University of Wisconsin graduating Cum Laude, Order of the Coif and Dean's List.

  • Lynne Aronson

    VP of Regulatory and Quality

    Ms. Aronson has 25 years of experience in the medical device industry, focusing on domestic and international regulatory affairs, quality assurance and clinical research in temperature management, interventional cardiology, hemodialysis and orthopedics. For the past 11 years, Ms. Aronson was the Director of RA/QA at Medivance, Inc. (C.R. Bard). Additionally, she has held positions at Global Therapeutics (Cook), COBE Renal Care (Gambro), Acufex Microsurgical (Smith & Nephew), Medical Device Consultants, Inc., and Duke University Medical Center. Ms. Aronson received a Bachelor's of Science in Biomedical Engineering from Duke University.